Veraxa Biotech Holding AG (VRXA) Form 424B5 — Aug 10, 2026
Veraxa Biotech filed a 424B5 prospectus supplement registering the resale of up to 25,000,000 ordinary shares held by Lincoln Park Capital Fund under their May 27, 2026 purchase agreement. The company may sell up to $50,000,000 of shares to Lincoln Park at its sole discretion over a 24-month term and receives no proceeds from Lincoln Park's own resales. The purchase price is formula-based on prevailing market prices, and VRXA closed at $1.99 on August 7, 2026.
Key figures
- Debt Amount
- $27,500,000 principal of High Trail senior secured note disclosed in Recent Developments
- Maturity Date
- 2027 (HTC Note, 15-month term from June 15, 2026 closing, amortizing monthly from month 6)
- Gross Proceeds
- up to $50,000,000 to the company from sales to Lincoln Park over the 24-month facility term
- Offering Price
- market-based purchase price formulas; VRXA closing price $1.99 on August 7, 2026
- Shares Offered
- up to 25,000,000 ordinary shares (including 340,910 commitment shares already issued)
- Shares Outstanding
- 166066903
- Vsop options
- 1422251
- Earnout shares
- 5000000
- Accumulated deficit
- CHF 66.6 million (December 31, 2025)
- Cantor deferred fee
- $12,045,000 (modified to include 3,500,000 ordinary shares)
- Facility term months
- 24
- Warrant exercise price
- $11.50
- Purchase agreement date
- May 27, 2026
- Commitment shares issued
- 340910
- Beneficial ownership limit
- 4.99% (may be increased to 9.99%)
- Warrant shares outstanding
- 21828044
- Warrant closing price vrxaw
- $0.096 (August 7, 2026)
Price after filing
1 day: +2.2%7 days: +0.5%30 days: -13.5%
Close on the filing date to close N calendar days later (from $1.85). Historical, not a forecast.
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.